{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:04:40Z","timestamp":1790521480812,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.omtm.2020.06.016","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T21:18:11Z","timestamp":1592947091000},"page":"415-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy"],"prefix":"10.1016","volume":"18","author":[{"given":"Virginie","family":"Mariot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Le Guiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e8s","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Montus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Blot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Torelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Voit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dumonceaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2020.06.016_bib1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(12)61897-2","article-title":"Muscular dystrophies","volume":"381","author":"Mercuri","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2020.06.016_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/nat.2017.0682","article-title":"Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtm.2020.06.016_bib3","doi-asserted-by":"crossref","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2020.06.016_bib4","doi-asserted-by":"crossref","first-page":"e15858","DOI":"10.1097\/MD.0000000000015858","article-title":"Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy","volume":"98","author":"Alfano","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.omtm.2020.06.016_bib5","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.nmd.2010.06.014","article-title":"North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy","volume":"20","author":"Mazzone","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2020.06.016_bib6","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mus.21544","article-title":"The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy","volume":"41","author":"McDonald","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2020.06.016_bib7","doi-asserted-by":"crossref","first-page":"e0160195","DOI":"10.1371\/journal.pone.0160195","article-title":"Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy","volume":"11","author":"Mercuri","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2020.06.016_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.nmd.2019.02.002","article-title":"Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study","volume":"29","author":"Ricotti","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2020.06.016_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0002-8703(03)00119-4","article-title":"The 6-minute walk test: how important is the learning effect?","volume":"146","author":"Wu","year":"2003","journal-title":"Am. Heart J."},{"key":"10.1016\/j.omtm.2020.06.016_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/dmcn.94_12887","article-title":"Role of motivation on performance of the 6-minute walk test in boys with Duchenne muscular dystrophy","volume":"57","author":"Alfano","year":"2015","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.omtm.2020.06.016_bib11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.nmd.2016.09.002","article-title":"Muscle MRI in Duchenne muscular dystrophy: Evidence of a distinctive pattern","volume":"26","author":"Polavarapu","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2020.06.016_bib12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1177\/0192623317734823","article-title":"Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification","volume":"45","author":"Wilson","year":"2017","journal-title":"Toxicol. Pathol."},{"issue":"s2","key":"10.1016\/j.omtm.2020.06.016_bib13","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.3233\/JND-150102","article-title":"Circulating Biomarkers for Duchenne Muscular Dystrophy","volume":"2","author":"Aartsma-Rus","year":"2015","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2020.06.016_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/187152210793663748","article-title":"Extracellular Regulation of Myostatin: A Molecular Rheostat for Muscle Mass","volume":"10","author":"Lee","year":"2010","journal-title":"Immunol. Endocr. Metab. Agents Med. Chem."},{"key":"10.1016\/j.omtm.2020.06.016_bib15","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41467-017-01486-4","article-title":"Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches","volume":"8","author":"Mariot","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2020.06.016_bib16","first-page":"1253","article-title":"Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy","volume":"7","author":"Barth\u00e9l\u00e9my","year":"2014","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtm.2020.06.016_bib17","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1038\/mt.2014.151","article-title":"Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients","volume":"22","author":"Le Guiner","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.06.016_bib18","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2020.06.016_bib19","doi-asserted-by":"crossref","first-page":"9306","DOI":"10.1073\/pnas.151270098","article-title":"Regulation of myostatin activity and muscle growth","volume":"98","author":"Lee","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2020.06.016_bib20","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/mt.2013.121","article-title":"AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy","volume":"21","author":"Le Hir","year":"2013","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050120301406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050120301406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:22:11Z","timestamp":1762420931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050120301406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":20,"alternative-id":["S2329050120301406"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2020.06.016","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2020.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors.","name":"copyright","label":"Copyright"}]}}